The most widely used panel is based on the expression of cytokeratin 5/6 (CK5/6) and/or the epidermal growth factor receptor (EGFR) in tumors that are triple-negative [12]; however, no uniform consensus exists as to what is the optimal immunnohistochemical panel to identify basal-like breast cancer. Here, EGFR is linked to breast carcinoma.